Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Down 72.9% in June

Acasti Pharma Inc. (NASDAQ:ACST) was the recipient of a significant decrease in short interest in the month of June. As of June 30th, there was short interest totalling 1,600 shares, a decrease of 72.9% from the June 15th total of 5,900 shares. Based on an average daily volume of 14,300 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s shares are sold short.

Acasti Pharma Stock Up 3.3 %

Shares of NASDAQ ACST opened at $3.13 on Friday. The firm’s fifty day moving average is $2.94 and its 200 day moving average is $2.98. Acasti Pharma has a 52 week low of $1.72 and a 52 week high of $3.59. The company has a market cap of $29.42 million, a price-to-earnings ratio of -2.17 and a beta of 1.55.

Acasti Pharma (NASDAQ:ACST) last announced its quarterly earnings results on Friday, June 21st. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.30. Equities research analysts anticipate that Acasti Pharma will post -1.14 earnings per share for the current year.

About Acasti Pharma

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.